BELLUS HEALTH INC
Share · CA07987C2040 · BLU · A2PQKK (XTSE)
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of BELLUS HEALTH INC
No Price
Company Profile for BELLUS HEALTH INC Share
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada.
Company Data
Name BELLUS HEALTH INC
Company BELLUS Health Inc.
Symbol BLU
Website
https://www.bellushealth.com
Primary Exchange 
TSX
TSX
WKN A2PQKK
ISIN CA07987C2040
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Roberto Francesco Bellini
Market Capitalization 2 Mrd.
Country Canada
Currency CAD
Employees 0,1 T
Address 275 Armand-Frappier Boulevard, H7V 4A7 Laval
IPO Date 2000-10-27
Dividends from 'BELLUS HEALTH INC'
| Ex-Date | Dividend per Share |
|---|---|
| 29.12.2010 | 0,02 USD |
| 07.04.2009 | 0,003 USD |
| 24.12.2008 | 0,07 USD |
| 08.10.2008 | 0,002 USD |
| 09.07.2008 | 0,007 USD |
Stock Splits
| Date | Split |
|---|---|
| 19.08.2019 | 1:3.6 |
| 29.05.2012 | 1:30 |
ID Changes
| Date | From | To |
|---|---|---|
| 31.03.2008 | NRMX | BLU |
Ticker Symbols
| Name | Symbol |
|---|---|
| NASDAQ | BLU |
More Shares
Investors who hold BELLUS HEALTH INC also have the following shares in their portfolio:
